Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: An observational cohort study

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 113-120

  Kojima, Toshihisa ^a   Yabe, Yuichiro ^b   Kaneko, Atsushi ^c   Takahashi, Nobunori ^a   Funahashi, Koji ^a   Kato, Daizo ^a   Hanabayashi, Masahiro ^a   Asai, Shuji ^a   Hirabara, Shinya ^a   Asai, Nobuyuki ^d   Hirano, Yuji ^e   Hayashi, Masatoshi ^f   Miyake, Hiroyuki ^g   Kojima, Masayo ^d   Ishiguro, Naoki ^a,h  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^f NAGANO RED CROSS HOSPITAL   (Japan)

^g Ichinomiya Municipal Hospital   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biologics; Methotrexate; Rheumatoid arthritis; Tocilizumab

Indexed keywords

METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COHORT ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

EID: 84928726892     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu302     Document Type: Article

References (34)

1. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Jacobs JW. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. Rheumatology 2012;51(Suppl 4):iv27-33.
3. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73: 492-509.
4. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68: 1100-4.
5. Soliman MM, Ashcroft DM, Watson KD et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
6. Listing J, Strangfeld A, Rau R et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
7. Lee SJ, Chang H, Yazici Y et al. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol 2009;36:1611-7.
8. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162-7.
9. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
10. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58: 2968-80.
11. Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9.
12. Nakashima Y, Kondo M, Harada H et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20:343-52.
13. Yamanaka H, Tanaka Y, Inoue E et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011; 21:122-33.
14. Yabe Y, Kojima T, Kaneko A et al. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) study. Mod Rheumatol 2013;23:245-53.
15. Weinblatt ME, Kremer J, Cush J et al. Tocilizumab as monotherapy or in combination with nonbiologic diseasemodifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res 2013;65:362-71.
16. Kojima T, Kaneko A, Hirano Y et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study. Mod Rheumatol 2012;22:339-45.
17. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
19. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
20. Kojima T, Kaneko A, Hirano Y et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol 2012;22: 370-5.
21. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381: 1541-50.
22. Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
23. Gorter SL, Bijlsma JW, Cutolo M et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
24. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.
25. Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
26. Yamanaka H, Tanaka Y, Sekiguchi N et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007;17: 28-32.
27. Sokka T, Toloza S, Cutolo M et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009;11:R7.
28. Jawaheer D, Maranian P, Park G et al. Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 2010;37: 2475-85.
29. Jawaheer D, Messing S, Reed G et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res 2012;64: 1811-8.
30. Jawaheer D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis- results from the DANBIO registry. J Rheumatol 2012;39: 46-53.
31. Katz PP. Education and self-care activities among persons with rheumatoid arthritis. Soc Sci Med 1998;46: 1057-66.
32. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008;27:883-9.
33. Pascual-Ramos V, Contreras-Yanez I. Motivations for inadequate persistence with disease modifying antirheumatic drugs in early rheumatoid arthritis: the patient's perspective. BMC Musculoskelet Disord 2013; 14:336.
34. Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology 2004; 43:1390-7.